tradingkey.logo

TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat

ReutersJan 14, 2026 1:46 PM

Shares of drugmaker TG Therapeutics TGTX.O up about 10% at $30.64 premarket

TGTX expects total revenue for 2026 in the range of $875 million to $900 million, compared with estimates of $895.63 million, according to data compiled by LSEG

Expects total revenue for 2025 at $616 million, above analysts' estimates of $606.6 million

TGTX expects 2025 U.S. sales of $594 million for its multiple sclerosis drug, Briumvi, up about 92% from a year earlier

Jefferies analysts expect data for subcutaneous version of Briumvi, which is expected by the end of 2026, to be "a large inflection point"

Shares fell marginally in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI